Group 1 - The core point of the news is that Sai Sheng Pharmaceutical (300485.SZ) announced a share reduction plan by its controlling shareholders and actual controllers' concerted actors, Ma Li and Liu Shuqin, who plan to reduce their holdings by up to 9,633,328 shares, representing 2% of the total share capital [1] - The planned share reduction will occur within three months from October 21, 2025, to January 20, 2026, through centralized bidding and block trading [1] - As of the announcement date, Ma Li holds 29,846,791 shares (6.2% of total shares), and Liu Shuqin holds 8,748,000 shares (1.82% of total shares) [1] Group 2 - In 2024, Sai Sheng Pharmaceutical reported operating revenue of 416.48 million yuan, a decrease of 12.61% compared to 2023 [2][3] - The net profit attributable to shareholders was -68.85 million yuan, a decline of 166.90% from the previous year [2][3] - The net profit after deducting non-recurring gains and losses was 11.76 million yuan, a significant improvement from -42.09 million yuan in the previous year, marking a 127.94% increase [2][3] - The net cash flow from operating activities was 135.97 million yuan, showing a substantial increase of 541.05% year-on-year [2][3]

Policy Developments - The National Healthcare Security Administration (NHSA) released the 11th batch of national drug centralized procurement documents, emphasizing principles of "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [2] - The new procurement strategy optimizes "anchor prices" by not simply selecting the lowest bid but using the higher value between the average of "comparable unit prices" and the lowest "comparable unit price" at 50% [2] Drug and Device Approvals - Fosun Pharma announced that its subsidiary, Fuhong Hanlin, received EU approval for two drugs, BILDYOS® and BILPREVDA®, for treating osteoporosis in high-risk patients [4] - Renfu Pharma's subsidiary received a tentative FDA approval for Oxcarbazepine extended-release tablets, aimed at treating partial seizures in patients aged 6 and above, with a total R&D investment of approximately 15 million RMB [5] Capital Markets - LuKang Pharmaceutical plans to acquire a 1.9231% stake in Shandong Lukang Hecheng Pharmaceutical Co., with the final amount to be determined through bidding [7] - GE Healthcare responded to rumors about selling its Chinese business, stating its commitment to providing high-quality medical services in China [8] Industry Events - The NHSA announced the interim results of expert reviews for the 2025 National Basic Medical Insurance Directory and commercial insurance innovative drug directory adjustments [10][11] - In the first half of 2025, China's innovative drug licensing transactions reached nearly $66 billion, indicating a significant increase in international recognition and commercial value of Chinese innovative drugs [12] - The National Medical Products Administration established a review center in the Beijing-Tianjin-Hebei region to enhance drug and medical device evaluation services [13] - Approximately 100 rare disease drugs have been included in the basic medical insurance directory, covering 42 types of rare diseases [14]

Core Viewpoint - Recently, Sai Sheng Pharmaceutical (300485) announced that shareholders Ma Li and Liu Shuqin plan to reduce their holdings in the company due to personal funding needs [1][4]. Shareholder Reduction Plan - Ma Li and Liu Shuqin intend to reduce their holdings by a total of up to 9,633,328 shares, which is no more than 2% of the company's total share capital of 481,666,400 shares, within three months starting from October 21, 2025 [4]. - The shares to be sold are from those issued before the company's initial public offering, including any shares increased due to rights distributions during their holding period [4]. Financial Implications - Based on the latest closing price of 12.08 yuan per share, the total cashing out from this reduction could amount to approximately 120 million yuan [5]. - As of the announcement date, Ma Li holds 29,846,791 shares (6.2% of total shares), while Liu Shuqin holds 8,748,000 shares (1.82% of total shares) [5]. Company Performance - Sai Sheng Pharmaceutical's main business includes the research, production, and sales of injectable drugs, focusing on immunological, neurological, and cardiovascular medications [6]. - The company's net profit has declined for three consecutive years, with figures of 205 million yuan, 103 million yuan, and a loss of 68.85 million yuan for the years 2022, 2023, and 2024, respectively, reflecting year-on-year declines of 49.11%, 49.73%, and 166.90% [6][7]. - In the first half of 2025, the company reported total revenue of 197 million yuan, a year-on-year decrease of 8.40%, while the net profit attributable to shareholders was 47.78 million yuan, indicating a turnaround from previous losses [7].

Core Viewpoint - The announcement from Sai Sheng Pharmaceutical indicates that two significant shareholders plan to reduce their holdings in the company within a specified timeframe, which may impact the stock's performance and investor sentiment [1] Shareholder Information - Ms. Ma Li holds 29,846,791 shares, representing 6.2% of the total share capital of 481,666,400 shares [1] - Ms. Liu Shuqin holds 8,748,000 shares, accounting for 1.82% of the total share capital [1] - Both Ms. Ma and Ms. Liu are acting in concert with the company's controlling shareholder, Mr. Ma Biao [1] Planned Share Reduction - Ms. Ma and Ms. Liu plan to reduce their holdings by a total of up to 9,633,328 shares, which is not more than 2% of the total share capital [1] - The reduction will occur within three months starting from 15 trading days after the announcement, specifically from October 21, 2025, to January 20, 2026 [1]

Mergers and Acquisitions - Haichang New Materials plans to acquire 51% equity of Shenzhen Xinwei Communication Technology Co., Ltd. through cash payment, with the final transaction price based on the audited valuation [1] - West Materials' subsidiary Xi'an Filter plans a major asset restructuring, leading to a stock suspension from September 22, 2025, until before October 21, 2025 [2] Shareholding Changes - Sai Sheng Pharmaceutical's shareholders plan to reduce their holdings by up to 2% of the company's total shares, equating to a maximum of 9.6333 million shares [3] - *ST Tianlong's major shareholder plans to reduce holdings by up to 1%, totaling no more than 2.0051 million shares [4] - Softcom Power's controlling shareholder and its concerted parties plan to reduce holdings by up to 2%, amounting to a maximum of 19.0588 million shares [5] Investment Agreements - Baoli International intends to invest in Nanjing Hongtai Semiconductor Technology Co., Ltd. for 1% to 3% equity, within 5% of the latest audited net assets [6] - Ankai Micro plans to invest 20 million yuan to acquire 4% equity in Vision Future, focusing on the intelligent vision field [7] Financial Reporting Issues - Fudan Fuhua reported inflated profits totaling 81.0655 million yuan across three annual reports due to false records [8] - Juewei Foods failed to disclose actual operating income from 2017 to 2021, leading to a proposed fine of 4 million yuan and a change in stock name to "ST Juewei" [9] - ST New Power is under investigation for suspected information disclosure violations, with normal operations ongoing during the investigation [10]

Core Viewpoint - The shareholders of Sai Sheng Pharmaceutical plan to reduce their holdings by up to 9.63 million shares, representing no more than 2% of the company's total share capital [1] Shareholder Information - Shareholder Ma Li holds 29.84 million shares, accounting for 6.2% of the total share capital [1] - Shareholder Liu Shuqin holds 8.748 million shares, accounting for 1.82% of the total share capital [1] - Both Ma Li and Liu Shuqin are acting in concert with the company's controlling shareholder, Ma Qiang [1]

马丽女士和刘淑芹女士计划在自本公告披露之日起15个交易日后的3个月内（即：2025年10月21日至 2026年1月20日），通过集中竞价和大宗交易方式减持公司股份数量合计不超过9,633,328股，即不超过 公司当前总股本481,666,400股的2%。 格隆汇9月19日丨赛升药业(300485.SZ)公布，截至本公告披露日，马丽女士持有公司股份29,846,791股 （占公司当前总股本481,666,400股的6.2%），刘淑芹女士持有公司股份8,748,000股（占公司当前总股 本481,666,400股的1.82%），马丽女士和刘淑芹女士均为公司控股股东、实际控制人马骉先生的一致行 动人。 ...

Group 1 - The company Saisheng Pharmaceutical announced that two shareholders, Ma Li and Liu Shuqin, hold 29.8468 million shares and 8.748 million shares, representing 6.2% and 1.82% of the total shares respectively [1] - The shareholders plan to reduce their holdings by a total of no more than 9.6333 million shares, which is up to 2% of the total shares, between October 21, 2025, and January 20, 2026 [1] - The reduction will be executed through centralized bidding and block trading, with each method accounting for no more than 4.8167 million shares, or 1% of the total shares [1]

Group 1 - The core point of the news is that Beijing Saiseng Pharmaceutical Co., Ltd. announced a plan for share reduction by its major shareholders, which will not affect the company's control or governance structure [1][2] - Major shareholders Ma Li and Liu Shuqin plan to reduce their holdings by a total of up to 9.63 million shares, representing no more than 2% of the company's total share capital [1] - Ma Li currently holds 29.8468 million shares (6.2% of total shares), while Liu Shuqin holds 8.748 million shares (1.82% of total shares) [1] Group 2 - The reduction will occur between October 21, 2025, and January 20, 2026, through centralized bidding and block trading [1] - The reason for the reduction is personal funding needs, and the shares being sold were acquired prior to the company's initial public offering [1] - The reduction price will be determined based on market conditions at the time of sale, with a minimum price set at the initial public offering price [1]

南财智讯9月19日电，赛升药业公告，公司控股股东、实际控制人的一致行动人马丽及刘淑芹计划在 2025年10月21日至2026年1月20日期间，通过集中竞价和大宗交易方式减持公司股份合计不超过 963.3328万股，即不超过公司总股本的2%。减持原因是自身资金需求。本次减持计划符合相关法律法 规及规范性文件的规定。 ...